Pluristem Therapeutics Inc. (PSTI) - 10-Q Summary
Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (a development stage company)
Reporting Period: Nine months ended March 31, 2010 (Unaudited)
Business Overview: The Company is focused on the research and development of adherent stromal cells production technology and the commercialization of cell therapy products, specifically the PLX-PAD product for peripheral artery disease. The Company has not generated any revenues since inception and relies on equity financing and government grants to fund operations.
Key Financial Metrics
| Metric (in thousands USD) | Nine Months Ended Mar 31, 2010 | Nine Months Ended Mar 31, 2009 | Three Months Ended Mar 31, 2010 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5,711) | $(5,069) | $(2,263) |
| Loss Per Share (Basic & Diluted) | $(0.34) | $(0.52) | $(0.13) |
| Operating Cash Flow | $(3,744) | $(3,230) | N/A |
| Cash and Cash Equivalents (Ending) | $1,119 | $1,724 | $1,119 |
| Total Assets | $4,085 | $4,463 | $4,085 |
| Total Liabilities | $1,457 | $1,069 | $1,457 |
| Accumulated Deficit | $(38,363) | $(32,652) | $(38,363) |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 13% for the nine-month period compared to the prior year, driven primarily by higher Research and Development (R&D) expenses.
- R&D Expenses: Net R&D expenses increased 40% to $3.3 million (from $2.4 million) due to clinical trial progress, patient recruitment costs, and the hiring of 11 new R&D employees.
- G&A Expenses: General and Administrative expenses decreased 6% to $2.4 million, primarily due to a reduction in stock-based compensation.
- Liquidity: Cash and cash equivalents decreased by $1.2 million to $1.1 million, reflecting operating cash burn partially offset by financing activities.
- Financial Income: Financial expenses turned into a net income of $6,000 for the nine-month period, compared to an expense of $150,000 in the prior year, largely due to exchange rate adjustments and the absence of losses from marketable securities sales.
Guidance, Outlook, and Risks
- Clinical Progress: The Company announced interim results from Phase I clinical trials for PLX-PAD (treatment for critical limb ischemia) involving 21 patients. Results suggest the product is safe, well-tolerated, and effective according to interim parameters.
- Capital Requirements: The Company estimates net operating cash expenses of approximately $7 million for the next 12 months. Management believes current funds, including $2.7 million raised in a private placement on April 27, 2010, and an approved grant from the Israeli Office of the Chief Scientist (OCS), will sustain operations until at least Q1 2011.
- Going Concern: The filing reiterates substantial doubt about the Company's ability to continue as a going concern due to the lack of revenue and history of losses. Continued financing is required.
- Subsequent Event: On April 27, 2010, the Company closed a private placement raising approximately $2.7 million through the sale of common stock and warrants.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.1 million cash balance plus the $2.7 million subsequent financing against the projected $7 million annual burn rate.
- Grant Dependency: Confirm the status and disbursement schedule of the R&D grant from the Israeli Office of the Chief Scientist (OCS).
- Dilution Risk: Review the terms of the April 27, 2010 private placement and outstanding warrants/options (approx. 12.7 million total) to assess potential dilution in future financing rounds.
- Clinical Milestones: Monitor the completion of Phase I trials and the regulatory pathway for Phase II trials to validate the commercial viability of PLX-PAD.
- Stock-Based Compensation: Analyze the impact of non-cash stock-based compensation ($1.3 million for the nine months) on future cash burn if converted to cash salaries.